Pyrazolotriazines as inhibitors of nucleases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F17%3A00099613" target="_blank" >RIV/00216224:14310/17:00099613 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20171220&DB=&locale=en_EP&CC=EP&NR=2957562B1&KC=B1&ND=4#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20171220&DB=&locale=en_EP&CC=EP&NR=2957562B1&KC=B1&ND=4#</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Pyrazolotriazines as inhibitors of nucleases
Original language description
The present invention relates to substituted heterocycles as inhibitors of nudeases MUS81 and MRE11, pharmaceutical compositions containing the compounds, and pharmaceutical use of the compounds and compositions in the treatment of the diseases such as, for example, cancer.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10600 - Biological sciences
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP2957562
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Dec 20, 2017
Owner name
Masarykova univerzita
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence